EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Advances in PLGA-Based Drug Delivery Systems for Glioblastoma Treatment

Salona Roy, Daniel Alday, Qi Cai iD

International Journal of Nanomedicine · 2025

DOI: 10.2147/ijn.s563730 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Salona Roy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, 70803, USA. Hauptthemen laut MEDLINE: Glioblastoma, Lactic Acid, Polyglycolic Acid, Brain Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most aggressive primary brain tumor, with median survival rates remaining dismally low despite standard-of-care therapies including maximal resection, radiation, and chemotherapy. A significant challenge in GBM therapy is the inability of conventional drugs to achieve therapeutic concentrations in the tumor due to the restrictive nature of the blood-brain barrier (BBB) and the complex tumor microenvironment (TME), which includes high interstitial pressure, abnormal vasculature, and dense extracellular matrix that together hinder drug penetration and distribution. Nanoparticle-based drug delivery systems have emerged as promising tools to circumvent the BBB and enhance drug delivery for GBM treatment. Among these, poly(lactic-co-glycolic acid) (PLGA) formulations stand out as one of the most widely used biodegradable carriers, which have been approved by the FDA for drug delivery applications. This review provides a comprehensive evaluation of the challenges and opportunities arising from the GBM microenvironment and their implications for the development of PLGA nanoparticle-based drug delivery systems. We compare commonly used PLGA nanoparticle synthesis techniques and analyze key GBM characteristics that impede drug transport, highlighting how tumor microenvironmental constraints govern nanoparticle engineering and delivery efficiency. We further evaluate the integration of multimodal therapies that affect both therapeutic delivery and outcomes. Critically, we identify persistent translational bottlenecks and outline specific research and engineering solutions to bridge preclinical efficacy and clinical translation. By integrating current evidence through a translational perspective, this review offers researchers and clinicians a strategic roadmap to guide future efforts toward more rational nanoparticle design and successful clinical translation for GBM therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaLactic AcidPolyglycolic AcidBrain NeoplasmsAntineoplastic AgentsNanoparticle Drug Delivery SystemNanoparticlesDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerHumansAnimalsBlood-Brain BarrierTumor Microenvironment

Stichwörter der Autor:innen

PLGA nanoparticlesblood-brain barrierdrug deliveryglioblastomatargeted therapytumor microenvironment

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerLactic AcidPolyglycolic AcidAntineoplastic AgentsNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, 70803, USA.

ORCID-Profile: Qi Cai

Zitieren

APA

Roy, S., Alday, D., & Cai, Q. (2025). Advances in PLGA-Based Drug Delivery Systems for Glioblastoma Treatment. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s563730

Vancouver

Roy S, Alday D, Cai Q. Advances in PLGA-Based Drug Delivery Systems for Glioblastoma Treatment. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s563730

BibTeX
@article{Roy2025,
  author = {Roy, Salona and Alday, Daniel and Cai, Qi},
  title = {Advances in PLGA-Based Drug Delivery Systems for Glioblastoma Treatment},
  journal = {International Journal of Nanomedicine},
  year = {2025},
  doi = {10.2147/ijn.s563730}
}
Kostenlos starten →